GALT Stock Price, Galectin Therapeutics Quote, Chart

Market Summary

USD3.24+0.10

Market Closed

3.18%

GALT Stock Price

View Fullscreen

GALT RSI Chart

GALT Valuation

Market Cap

195.1M

Price/Earnings (Trailing)

-4.76

Price/Free Cashflow

-5.69

GALT Price/Sales (Trailing)

GALT Profitability

Return on Equity

56.35%

Return on Assets

-158.47%

Free Cashflow Yield

-17.56%

GALT Fundamentals

GALT Earnings

Earnings (TTM)

-41.0M

Earnings Growth (Yr)

0.33%

Earnings Growth (Qtr)

-14.92%

Breaking Down GALT Revenue

52 Week Range

3.26

(Low)(High)

Last 7 days

-2.8%

Last 30 days

-7.1%

Last 90 days

81.6%

Trailing 12 Months

89.2%

How does GALT drawdown profile look like?

GALT Financial Health

Current Ratio

2.02

GALT Investor Care

Shares Dilution (1Y)

4.31%

Diluted EPS (TTM)

-0.74

Tracking the Latest Insider Buys and Sells of Galectin Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	zordani richard a. jr.	bought	3,520	3.52	1,000	-
Apr 24, 2024	lewis joel	bought	3,390	3.39	1,000	president and ceo
Apr 23, 2024	czirr james c	sold	-11,251	3.06	-3,677	-
Apr 22, 2024	czirr james c	sold	-65,248	3.06	-21,323	-
Apr 22, 2024	freeman kevin d	bought	7,450	2.98	2,500	-
Apr 09, 2024	freeman kevin d	acquired	-	-	2,063	-
Mar 01, 2024	lewis joel	sold	-299,065	1.96	-152,584	president and ceo
Jan 24, 2024	uihlein richard e	acquired	40,000	1.72	23,256	-
Jan 16, 2024	eldred kary	bought	892	1.7858	500	-
Dec 29, 2023	lewis joel	acquired	19,266	1.66	11,606	president and ceo

Which funds bought or sold GALT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	sold off	-100	-39,423	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-2,000	-	-%
May 15, 2024	WEDBUSH SECURITIES INC	unchanged	-	11,000	37,000	-%
May 15, 2024	SHEPHERD KAPLAN KROCHUK, LLC	unchanged	-	8,760	28,680	0.02%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-9.62	13,877	59,944	-%
May 15, 2024	Mariner, LLC	added	160	49,766	67,823	-%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-184,318	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-23.73	1,200	13,429	-%
May 15, 2024	CITADEL ADVISORS LLC	added	249	46,968	58,605	-%
May 15, 2024	Squarepoint Ops LLC	new	-	114,565	114,565	-%

Are Funds Buying or Selling GALT?

Are funds buying GALT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GALT

No. of Funds

Unveiling Galectin Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 01, 2023	10x fund, l.p.	9.6%	5,947,207	SC 13D/A

Recent SEC filings of Galectin Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
Apr 30, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	4	Insider Trading
Apr 25, 2024	5	Insider Trading
Apr 22, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Mar 29, 2024	10-K	Annual Report
Mar 29, 2024	8-K	Current Report

Peers (Alternatives to Galectin Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Galectin Therapeutics Inc News

Latest updates

Galectin Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.2%	26.00	28.00	22.00	20.00	20.00	21.00	18.00	26.00	34.00	42.00	38.00	33.00	23.00	30.00	34.00	41.00	44.00	48.00	51.00	53.00	8.00
Current Assets	-8.1%	25.00	28.00	22.00	19.00	20.00	21.00	17.00	26.00	34.00	42.00	38.00	33.00	23.00	29.00	34.00	41.00	44.00	48.00	50.00	53.00	7.00
Cash Equivalents	-8.2%	24.00	26.00	20.00	18.00	18.00	19.00	16.00	24.00	32.00	40.00	37.00	32.00	21.00	27.00	33.00	41.00	43.00	47.00	50.00	52.00	7.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	9.7%	97.00	88.00	73.00	71.00	63.00	53.00	40.00	41.00	40.00	39.00	29.00	16.00	5.00	5.00	3.00	4.00	1.00	3.00	1.00	1.00	1.00
Current Liabilities	-19.4%	13.00	16.00	11.00	10.00	12.00	13.00	10.00	11.00	10.00	9.00	8.00	6.00	5.00	5.00	2.00	4.00	1.00	3.00	1.00	1.00	1.00
Shareholder's Equity	-17.5%	-72.81	-61.96	-	-	-44.37	-33.92	-	-	-	1.00	8.00	15.00	17.00	22.00	30.00	35.00	41.00	44.00	48.00	50.00	5.00
Retained Earnings	-3.2%	-365	-354	-344	-330	-321	-309	-298	-290	-280	-270	-263	-254	-246	-240	-232	-226	-219	-216	-211	-208	-205
Additional Paid-In Capital	0.2%	292	292	291	277	276	275	274	273	272	271	270	270	262	262	261	261	260	260	258	258	210
Shares Outstanding	0.5%	62.00	62.00	62.00	60.00	60.00	59.00	59.00	59.00	59.00	59.00	58.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	63.00	-	-	-	59.00	-	-	-	139	-	-	-	126	-	-	-	166	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-157.4%	-12,105	-4,702	-7,637	-9,833	-10,793	-7,239	-8,347	-7,428	-8,042	-6,951	-4,998	-5,977	-6,382	-5,414	-8,212	-2,604	-4,371	-3,759	-1,475	-2,330	-3,284
Share Based Compensation	21.5%	604	497	586	516	662	681	681	647	858	654	587	581	254	567	408	394	430	414	414	443	412
Cashflow From Financing	0%	10,000	10,000	10,033	10,000	10,000	10,000	-	-	-	9,999	10,000	16,815	-	-	-	44.00	219	902	-231	47,401	2,003

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GALT Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 8,054	$ 8,799
General and administrative	1,594	1,543
Total operating expenses	9,648	10,342
Total operating loss	(9,648)	(10,342)
Other income (expense):
Interest income	80	44
Change in fair value of derivatives	(869)	(769)
Interest expense	(1,052)	(460)
Total other income (expense)	(1,841)	(1,185)
Net loss	(11,489)	(11,527)
Preferred stock dividends	(8)	0
Net loss applicable to common stockholders	$ (11,497)	$ (11,527)
Net loss per common share - basic (in dollars per share)	$ (0.19)	$ (0.19)
Net loss per common share - diluted (in dollars per share)	$ (0.19)	$ (0.19)
Weighted average common shares outstanding - basic (in shares)	61,976	59,480
Weighted average common shares outstanding - diluted (in shares)	61,976	59,480

GALT Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 23,555	$ 25,660
Prepaid expenses and other current assets	1,905	2,050
Total current assets	25,460	27,710
Other assets	430	490
Total assets	25,890	28,200
Current liabilities:
Accounts payable	3,797	6,431
Accrued expenses and other	8,836	9,182
Accrued dividends payable	0	63
Total current liabilities	12,633	15,676
Convertible notes payable and accrued interest, net of discounts - related party (Note 3)	31,139	30,902
Derivative liabilities (Note 4)	1,873	1,004
Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Notes 9 and 10)	51,324	40,839
Other liabilities	7	20
Total liabilities	96,976	88,441
Commitments and contingencies (Note 11)
Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at March 31, 2024 and December 31, 2023, redemption value: $8,098,000, liquidation value: $1,760,000 at March 31, 2024	1,723	1,723
Stockholders' equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2024 and December 31, 2023, respectively	0	0
Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,235,000 issued and outstanding at March 31, 2024 and December 31, 2023, liquidation value $1,235,000 at March 31, 2024	500	500
Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, 62,148,134 and 61,852,914 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	61	61
Additional paid-in capital	292,499	291,847
Retained deficit	(365,869)	(354,372)
Total stockholders' equity (deficit)	(72,809)	(61,964)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$ 25,890	$ 28,200

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

CEO	Mr. Joel Lewis
WEBSITE	https://galectintherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Galectin Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Galectin Therapeutics Inc? What does GALT stand for in stocks?

GALT is the stock ticker symbol of Galectin Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Galectin Therapeutics Inc (GALT)?

As of Thu May 16 2024, market cap of Galectin Therapeutics Inc is 195.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GALT stock?

You can check GALT's fair value in chart for subscribers.

What is the fair value of GALT stock?

You can check GALT's fair value in chart for subscribers. The fair value of Galectin Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Galectin Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GALT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Galectin Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether GALT is over valued or under valued. Whether Galectin Therapeutics Inc is cheap or expensive depends on the assumptions which impact Galectin Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GALT.

What is 5 year return on Galectin Therapeutics Inc's stock?

In the past 10 years, Galectin Therapeutics Inc has provided -0.117 (multiply by 100 for percentage) rate of return.